Results 61 to 70 of about 3,260 (145)
Frontiers in Oncology, 2021 Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang +17 more
doaj +1 more source
, 2023 Video abstract for our matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic ...
Adam S. Kittai (15088179) +8 more
core +1 more source
European Journal of Haematology, Volume 117, Issue 4, Page 849-863, October 2026.ABSTRACT Extranodal marginal zone lymphoma (EMZL) represents a unique paradigm among indolent B‐cell neoplasms, in which lymphomagenesis is frequently driven by chronic antigenic stimulation within tissue‐specific microenvironments. Persistent infectious or autoimmune triggers promote the development of ectopic lymphoid tissue and sustain B‐cell ...
Mamdouh Skafi +15 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang +10 more
wiley +1 more source
Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma [PDF]
Zanubrutinib and acalabrutinib have demonstrated efficacy in separate single-arm clinical trials in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Shah, B. +9 more
core +1 more source
Blood Advances, 2019 : The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has proven to be efficacious in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases.
Gasim Dobie +9 more
doaj +1 more source
HemaSphere, Volume 10, Issue 9, September 2026.Abstract Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations.
Johanne U. Hermansen +24 more
wiley +1 more source
Oncology and TherapyIntroduction Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be
Talha Munir +12 more
doaj +1 more source
Hematological Oncology, Volume 44, Issue 5, September 2026.ABSTRACT Multiple targeted agents are available for first‐line treatment of chronic lymphocytic leukemia (CLL), yet the absence of mature head‐to‐head comparisons makes treatment selection challenging. The prospective, multicenter FIRST‐CLL study evaluated real‐world treatment allocation, and the contribution of biological, clinical, logistical and ...
Francesca Perutelli +27 more
wiley +1 more source
Blood Advances: Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib (ibr) revolutionized chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment, although treatment-related toxicities limit the use of some BTK inhibitors.
Mazyar Shadman +13 more
doaj +1 more source